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Abstract The flavonoid quercetin has recently been
reported to have neuroprotective effects, and the role of the
gamma-aminobutyric acid A alpha 5 subunit (GABAA a5)
receptor has been determined in some nervous system
disorders. The aim of this study was to identify the
molecular mechanism of the effect of quercetin adminis-
tered at anticonvulsive doses on the expression of the
GABAA a5 receptor gene in kainic acid (KA)-induced
seizures in mice. The experimental animals were divided
into four groups: control, KA, and KA ? quercetin at 50 or
100 mg/kg, respectively. The results showed a dose-de-
pendent reduction in the behavioral seizure score with
quercetin pre-treatment in the KA mouse model. Two
hours after the end of the 7-day treatment regimen,
expression of the GABAA a5 receptor gene in the hip-
pocampus was found to be increased in the KA group, but
this increase was reduced in the KA ? quercetin 50 or
100 mg/kg treatment groups. These results suggest that
expression of the GABAA a5 receptor could be a mecha-
nism for reducing seizure severity or may be a marker of
seizure severity. Further studies are necessary to clarify
quercetin’s mechanism of action and the relation of
GABAA a5 receptor gene expression to seizure severity.
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Introduction
Epilepsy is one of the most common neurological disorders
and affects approximately 1 % of the general population
[1]. Most of the antiepileptic drugs currently available
either control or reduce the occurrence of seizure. How-
ever, about one-third of patients with epilepsy have a
refractory form of the disease. Temporal lobe epilepsy
(TLE) is a form of partial epilepsy in adults [2]. Kainic acid
(KA) is used to induce TLE in model systems and causes
neuropathological and electroencephalographic manifesta-
tions that are observed in patients with TLE [3]. KA is a
potent excitotoxin [4], and its effects are mediated through
changes in the expression of the gamma-aminobutyric acid
A alpha 5 subunit (GABAA a5) receptor in the hip-
pocampus [5].
c-Aminobutyric acid (GABA) is one of the major inhi-
bitory neurotransmitters in the central nervous system. It
acts on receptors coupled to chloride channels [6], con-
trolling neuronal excitability by activating GABAA recep-
tors on neurons by two major modes—phasic and tonic.
Phasic inhibition is mediated by synaptic receptors, and
tonic inhibition is mediated by extrasynaptic receptors [7].
Tonic inhibitory conductance is predominantly mediated
by the GABAA a5 receptor [8], which is expressed in a
number of areas of the brain but expressed at a higher level
in the dendritic membrane of the principal cells of the
hippocampus [9].
Quercetin is a flavonoid found in vegetables and fruits
that has several biological effects [10], including antiox-
idative [11] and anti-inflammatory [12, 13] activities.
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Various studies have shown that quercetin has neuropro-
tective properties in central nervous system disorders,
including memory impairment [14–16], seizure [17, 18],
Huntington [19], and Parkinson’s disease [20]. In an earlier
study we showed that quercetin has anticonvulsant activity
in acute and chronic models of chemical kindling induced
by pentylenetetrazole (PTZ) [15, 18]. More recently,
Schipper et al. suggested that tonic GABAA receptors are a
potential target for the treatment of TLE [21].
The aim of this study was to determine the molecular
mechanism of the antiseizure effects of quercetin on the
expression of the GABAA a5 receptor gene in a KA model
of epilepsy in mice.
Materials and methods
A total of 48 male BALB/c mice (body weight 20–25 g)
were obtained from the Razi Institute (Karaj, Iran) and
housed under standard laboratory conditions. The mice
were maintained at constant room temperature (21 ± 2 C)
under a 12:12 h light:dark cycle with free access to food
and water. All animal experiments were performed in
accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) to minimize
the number of animals used and their suffering.
Quercetin and KA were purchased from Sigma (St.
Louis, MO). Other drugs used in the study included xyla-
zine (Loughrea Co., Galway, Ireland) and ketamine (Ro-
texmedica GmbH, Trittau, Germany). Quercetin was
dissolved in Tween 80 (0.8 % v/v) and KA was dissolved
in saline.
The mice were divided into four groups of 12 animals
each. The control group was given an intraperitoneal (i.p.)
injection of saline ? Tween 80 (10 ml/kg) daily for 7
days; on the last day, saline was injected 30 min after the
administration of saline ? Tween 80. The KA group was
given an i.p. injection of saline (10 ml/kg) daily for 7 days;
on the last day, KA (10 mg/kg, i.p.) was injected 30 min
after the administration of saline. In the two treatment
groups, the mice were given an i.p. injection of quercetin at
either 50 and 100 mg/kg daily for 7 days; on the last day,
KA (10 mg/kg, i.p.) was injected 30 min after the admin-
istration of quercetin.
Following the administration of KA, mice were
observed for behavioral changes over a period of 2 h. The
behavioral scores were as follows: 0, no response; 1,
immobility; 2, rigid posture; 3, scratching/circling/head
bobbing; 4, forelimb clonus/rearing/falling; 5, repetitive
pattern of 4; 6, severe tonic–clonic seizures [22]. Two
hours after the administration of KA, all animals were
anesthetized with an i.p. injection of ketamine (60 mg/ml)/
xylazine (6 mg/kg) and sacrificed. The hippocampus each
animal was immediately removed, cleaned with chilled
saline, and frozen until used for the molecular analysis.
In the molecular analysis, frozen hippocampus tissues
were homogenized and total RNA was extracted using
the Total RNA Extraction kit of Jena Bioscience GmbH
(Jena, Germany). The extracted RNA was then reverse
transcribed using the Revert Aid First Strand cDNA
Synthesis kit (Thermo Scientific–Fermentas, Waltham,
MA).
The primers used were GABRA5 (F: AGTTGGAGG-
CAAGAACAGTT; R: AAGGAGGGTTTGGGTCATG) for
the target gene and b-actin (F: TTACTGAGCTGCGTTT-
TACAC; R: ACAAAGCCATGCCAATGTTG) for the b-
actin gene (internal control). All primers were designed using
Gene Runner software (version 3.05). Quantitative reverse
transcription (RT)-PCR was used to detect GABAA a5 RNA
content in hippocampal tissues. A multiplex real-time PCR
assay using SYBR Green I was performed in final reaction
volumes of 20 ll containing 10 ll of SYBR Green I Master
Mix (Bioneer, Korea), 10 pmol of forward and reverse pri-
mers, and 20 ng total RNA-derived cDNAs. Thermal cycling
was performed using the ABI-7500 Sequence Detection
System (Applied Biosystems, Foster, CA) with cycling con-
ditions of 10 min at 95 C for the first denaturation step, fol-
lowed by 40 cycles at 95 C for 20 s and 58 C for 45 s;
dissociation was run at 95 C for 15 s, 60 C for 1 min and 95
C for 15 s. The 2-DDCt method was used to quantify data [23].
Data were expressed as the mean ± standard error of
the mean. The data reported were analyzed by using a one-
way analysis of variance accompanied by post hoc Turkey
test for multiple comparisons. The analysis was completed
using GraphPad Prism software (v5.04; GraphPad Soft-
ware, Inc., La Jolla, CA). P\ 0.05 was considered to
represent a statistically significant difference.
Results and discussion
In the mice model used in our study, KA administered at a
dose of 10 mg/kg caused seizures. Quercetin administered at
50 and 100 mg/kg, respectively, reduced the seizure score in
animals in a dose-dependent manner compared to the KA
group (P\ 0.05 and P\ 0.001, respectively) (Fig. 1).
Expression of the GABAA a5 receptor gene was
increased in the KA group compared to the control group at
2 h after the administration of KA (P\ 0.001). The
administration of quercetin doses at both 50 and 100 mg/kg
significantly decreased the expression of the GABAA a5
receptor gene compared to the KA group (P\ 0.001). The
difference in expression of the GABAA a5 receptor gene in
the quercetin and control groups was not significant
(Fig. 2).
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The results of our study show a dose-dependent reduc-
tion in the behavioral seizure score with quercetin pre-
treatment in a KA mouse model of epilepsy, as well as a
reduction in the expression of the GABAA a5 gene. In a
previous study, we found that quercetin administered at
anti-convulsive doses provided protection against memory
impairment caused by PTZ-induced chemical kindling
[17]. Other studies have also reported an increase in
GABAA a5 expression in KA and pilocarpine models
[24–26].
Increased expression of GABA receptors has been
reported in epilepsy, suggesting that compensatory mech-
anisms are involved in disease pathogenesis [26]. Long-
lasting decreases in the mRNA levels of the a5 and a2
GABAA receptor subunits in the CA1 area of the hip-
pocampus and increases in a5 in the dentate granule cell
layer have been observed in a pilocarpine model of epi-
lepsy [27].
In a model of febrile seizures, the administration of
lipopolysaccharide/KA to rat pups increased the protein
levels of the GABAA a5 receptor concomitant with
increasing interictal-like hippocampal activity and excita-
tion of the Shaffer collateral–CA1 pathway in adult rats
[28]. The authors of this study suggested that increased
levels might be related to a compensatory mechanism [28].
It has also been shown that status epilepticus (SE) induced
by KA causes early pyramidal neuron loss in the hip-
pocampus with a transient increase in GABAA/central
benzodiazepine (cBZR) density. These results suggest that
an increase in the GABA/cBZR expression for each neuron
might be a neuroprotective mechanism against the excito-
toxic effects of SE to protect cells against further seizures
[29]. Pretreatment with quercetin (100 mg/kg) has been
found to have a modulatory effect on the expression of the
GABAA subunits b1 and b3 receptor genes in a KA model
of epilepsy [30]. However, flavonoids have also been
shown to have an effect on ionotropic GABA receptors by
acting as a positive, neutralizing allosteric modulator,
suggesting that they could act on a variety of modulatory
receptors [31]. Quercetin administered at a dose of 30 lM
inhibited a1b1c2 GABAA and q1 GABAc receptors in
Xenopus laevis oocytes [32].
In conclusion, the expression of GABAA a5 may be a
mechanism for reducing seizure severity or may, as a
response to seizure activity, be a marker of seizure
severity. A better understanding of the time course of
changes in the expression of the GABAA a5 gene and
quantification of seizure severity (e.g., by electroen-
cephalography) are necessary to clarify quercetin’s
mechanism of action and the relation of a5 gene
expression to seizure severity.
Fig. 1 The effects of quercetin (doses 50 and 100 mg/kg) on seizure
scores in mice with kainic acid (KA)-induced seizures. The KA group
was administered an intraperitoneal (i.p.) dose of KA for 7
consecutive days, and on the last day, KA (10 mg/kg, i.p.) was
injected 30 min after the administration of saline. The treatment
groups were administered an i.p. dose of quercetin, either 50 (Q50) or
100 (Q100) mg/kg, for 7 days, and on the last day KA (10 mg/kg,
i.p.) was injected 30 min after the administration of quercetin. Data
are expressed as the mean ± standard error of the mean (SEM).
Asterisks indicate a significant difference (*P\ 0.05, ***P\ 0.001)
compared to the KA group according to the Tukey–Kramer test.
n = 12 mice in each group
Fig. 2 Effect of quercetin on the mRNA ratio of expression of the
GABAA a5 receptor gene in a KA model of seizure in the
hippocampus of mice. Data are expressed as the mean ± SEM.
***Significant difference at P\ 0.001 compared to controls,
•••significant different at P\ 0.001 compared to the KA group
according to the Tukey–Kramer test. n = 12 mice in each group
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